NGM Biopharmaceuticals Inc. (NASDAQ: NGM) is -8.73% lower on its value in year-to-date trading and has touched a low of $9.24 and a high of $32.05 in the current 52-week trading range. The NGM stock was last observed hovering at around $27.99 in the last trading session, with the day’s loss setting it -0.34% off its average median price target of $32.00 for the next 12 months. It is also 37.16% off the consensus price target high of $44.00 offered by 9 analysts, but current levels are 1.25% higher than the price target low of $28.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $27.65, the stock is -2.84% and 16.32% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.7 million and changing -1.21% at the moment leaves the stock 41.07% off its SMA200. NGM registered 50.60% gain for a year compared to 6-month gain of 39.29%. The firm has a 50-day simple moving average (SMA 50) of $26.48 and a 200-day simple moving average (SMA200) of $20.27.
The stock witnessed a 11.45% loss in the last 1 month and extending the period to 3 months gives it a 65.77%, and is -12.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.01% over the week and 5.82% over the month.
NGM Biopharmaceuticals Inc. (NGM) has around 186 employees, a market worth around $1.94B and $98.70M in sales. Profit margin for the company is -91.60%. Distance from 52-week low is 199.08% and -13.73% from its 52-week high. The company has generated returns on investments over the last 12 months (-14.90%).
NGM Biopharmaceuticals Inc. (NGM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for NGM Biopharmaceuticals Inc. (NGM) is a “Buy”. 9 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
NGM Biopharmaceuticals Inc. is expected to release its quarterly report on 05/20/2021 and quarterly earnings per share for the current quarter are estimated at -$0.46 with sales reaching $21.5M over the same period.The EPS is expected to shrink by -90.60% this year, but quarterly earnings will post -13.40% year-over-year. Quarterly sales are estimated to shrink -30.80% in year-over-year returns.
NGM Biopharmaceuticals Inc. (NGM) Top Institutional Holders
134 institutions hold shares in NGM Biopharmaceuticals Inc. (NGM), with 19.04M shares held by insiders accounting for 27.59% while institutional investors hold 85.30% of the company’s shares. The shares outstanding are 68.82M, and float is at 46.21M with Short Float at 7.99%. Institutions hold 61.77% of the Float.
The top institutional shareholder in the company is Svennilson Peter with over 18.02 million shares valued at $286.67 million. The investor’s holdings represent 26.11% of the NGM Shares outstanding. As of Sep 29, 2020, the second largest holder is RHO Capital Partners Inc with 3.77 million shares valued at $59.93 million to account for 5.46% of the shares outstanding. The other top investors are Blackrock Inc. which holds 2.44 million shares representing 3.54% and valued at over $38.89 million, while Point72 Asset Management, L.P. holds 2.34% of the shares totaling 1.61 million with a market value of $25.64 million.
NGM Biopharmaceuticals Inc. (NGM) Insider Activity
A total of 32 insider transactions have happened at NGM Biopharmaceuticals Inc. (NGM) in the last six months, with sales accounting for 8 and purchases happening 24 times. The most recent transaction is an insider sale by CHEN JIN-LONG, the company’s Chief Scientific Officer. SEC filings show that CHEN JIN-LONG sold 25,000 shares of the company’s common stock on Jan 04 at a price of $29.28 per share for a total of $0.73 million. Following the sale, the insider now owns 0.87 million shares.
NGM Biopharmaceuticals Inc. disclosed in a document filed with the SEC on Dec 14 that CHEN JIN-LONG (Chief Scientific Officer) sold a total of 25,000 shares of the company’s common stock. The trade occurred on Dec 14 and was made at $28.01 per share for $0.7 million. Following the transaction, the insider now directly holds 0.9 million shares of the NGM stock.
Still, SEC filings show that on Nov 02, CHEN JIN-LONG (Chief Scientific Officer) disposed off 25,000 shares at an average price of $17.70 for $0.44 million. The insider now directly holds 920,005 shares of NGM Biopharmaceuticals Inc. (NGM).